Biolab Sanus Farmaceutica

Name

Biolab Sanus Farmaceutica

Legal name

Biolab Sanus Farmacêutica Ltda.

Website

https://biolabfarma.com.br

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals (prescription and generic medications)

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Animal Food Manufacturing (3111), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Food And Kindred Products (2000)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Prescription pharmaceuticals
• Cardiology medications
• Generic medications
• Dermatology products
• Veterinary pharmaceuticals

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Products (Human Health): Revenue from branded pharmaceutical medications covering therapeutic areas including Cardiology, Dermatology, Gastroenterology, Mental Health (CNS), Women's Health, Urology, Pediatrics, Mobility/Orthopedics, and Hospital products. Products sold through pharmacies with prescription and OTC classifications.
2. Generic Medications (Biolab Genéricos): Generic pharmaceutical products acquired from Actavis Brasil in 2018, positioning Biolab as 3rd in market share in the participative market (2022). Manufactured in same facilities as branded products with same quality standards.
3. Veterinary Health Products (Avert): Veterinary pharmaceuticals, supplements, and dermocosmetics for pets (dogs and cats) with over 90 presentations. Division holds position among top 10 veterinary pharmaceutical companies for pet segment in Brazil.
4. Pet Nutrition (Snacks and Treats): Pet snacks and treats acquired from Petitos in 2023, now integrated under Avert Saúde Animal. Products developed with natural, high-quality ingredients including meat for high palatability.
5. Vitamins and Supplements: Dietary supplements including ID.Biolab line launched in 2019 for longevity and wellness, collagen supplements (Fascia line), and other nutritional products.
6. International Licensing and Export: Revenue from international licensing-out partnerships including Vonau Flash exports to Latin America, Canada platform via Exzell Pharma acquisition, and partnerships with distributors in multiple countries.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

Biolab Sanus Farmaceutica is a Brazilian pharmaceutical company that develops, manufactures, and distributes branded prescription medications, generic drugs, vitamins and dietary supplements, dermatological and cosmetic products, and veterinary pharmaceuticals across 12 therapeutic areas. The company operates an enterprise field sales force of 1,800 representatives detailing physicians, distributes products through Brazilian pharmacies, hospitals, and clinics, and exports internationally via licensing-out partnerships and the Exzell Pharma Canada platform.

Product overview

Biolab Sanus Farmacêutica operates as a diversified pharmaceutical group (Biolab&Co since 2026) with over 500 products across multiple business units. The portfolio is structured in three main divisions: (1) Biolab Farmacêutica - branded prescription medications and dermocosmetics including cardiology (Vonau Flash®, Nebivolol), dermatology (Pantogar® hair/nail line, Contractubex®), and general health supplements (Fascia® collagen, Reaox®); (2) Biolab Genéricos - generic medications with 3rd place market share; and (3) Animal Health - Avert® Saúde Animal veterinary products and Pet Nutrition® pet snacks. The company also operates patient programs (Saúde em Evolução), digital platforms (Biolab Studio for healthcare professionals), and distributes internationally through Exzell Pharma (Canada). The portfolio spans 12 therapeutic categories including cardiology, dermatology, gastroenterology, mental health, pediatrics, urology, women's health, and mobility.

Differentiator

Problem solved

Functional benefit

Brands

• Biolab Genéricos: Generic pharmaceutical products division offering quality generic medications at accessible prices.
• Avert® Saúde Animal
• Pet Nutrition®
• Exzell Pharma
• Vonau Flash®
• Biolab Studio
• Biolab em Casa

Products and services

• Vonau Flash Antiemetic medication for treatment of nausea and vomiting in adults and children, featuring orodispersible tablet technology for accelerated relief. Developed in partnership with USP. Benefits over 6 million patients annually and has generated R$30 million in royalties for USP.
• Nebivolol (Nebilet) Third-generation beta-blocker for cardiovascular conditions featuring beta-3 receptor agonism that increases nitric oxide production and provides metabolic benefits. Available with 25% discount through Saude em Evolucao program.

Quantifiable outcome

• Vonau Flash benefits over 6 million patients annually and has generated R$30 million in royalties for the University of São Paulo (90% of total royalties received by the institution)
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

21 partnerships are on record, tiered core, major and minor.

• Exzell PharmacoreStrategic or Co-development Partner · 1 January 2022Canadian pharmaceutical company acquired in 2022, establishing an international export platform from Canada with products for Gastroenterology, Dermatology, vitamins and supplements specialties.
• Merz PharmacoreStrategic or Co-development Partner · 1 January 2010Joint venture Merz-Biolab established in 2010, expanding international presence and launching the Procedure line including Xeomin botulinum toxin into the portfolio.
• University of São Paulo (USP)coreStrategic or Co-development PartnerPartnership with USP's Faculty of Pharmaceutical Sciences (FCF-USP) for development of Vonau Flash, one of the largest success cases of university-company partnership in Brazil with R$30 million in royalties to USP.
• Federal University of Rio Grande do Sul (UFRGS)coreStrategic or Co-development PartnerPartnership with UFRGS for development of Photoprot FPS 99 sunscreen using nanotechnology.
• MIT - Massachusetts Institute of TechnologymajorStrategic or Co-development PartnerMember of MIT's Industrial Liaison Program (MIT-ILP) for innovation excellence.
• FIOCRUZ - Oswaldo Cruz FoundationmajorStrategic or Co-development PartnerPartnership with Brazilian Oswaldo Cruz Foundation for health research.
• Instituto ButantanmajorStrategic or Co-development PartnerPartnership with Instituto Butantan for research collaboration.
• UNICAMP - University of CampinasmajorStrategic or Co-development PartnerPartnership with UNICAMP for research and development.
• UFMG - Federal University of Minas GeraismajorStrategic or Co-development PartnerPartnership with UFMG for research collaboration.
• FAPESPmajorStrategic or Co-development PartnerPartnership with São Paulo State Research Foundation FAPESP.
• UNIVAS - University of Vale do SapucaíminorStrategic or Co-development PartnerPartnership with UNIVAS for research collaboration.
• HC-FMUSP - Hospital das ClínicasmajorStrategic or Co-development PartnerPartnership with Hospital das Clínicas of USP for clinical research.
• Farma ColombiamajorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner in Colombia.
• Grupo Farma Del EcuadormajorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner in Ecuador.
• Farma VenezuelamajorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner in Venezuela.
• Eurofarma (Mexico)majorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner in Mexico.
• Biopharma Pharmaceutical CompanymajorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner in UAE.
• Yahmaa Medical CompanymajorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner in Saudi Arabia.
• Quimifar S.AminorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner.
• QuifatexminorChannel Partner/ Reseller/ DistributorLicensing-out distribution partner.
• ANPEIminorStrategic or Co-development PartnerMember of National Association of Research and Development of Innovative Companies (ANPEI) for strengthening commitment to national innovation.

Scale indicators12 records

Recent moves15 records

Expansion highlights6 records

Direct peers

• Cristália: Brazilian pharmaceutical company with strong presence in hospital products, generics, and specialty pharma. Competes with Biolab in B2B hospital channels and the generics segment.
• Aché Laboratórios: Major Brazilian pharmaceutical company with strong presence in cardiology, dermatology, and CNS therapeutic areas where Biolab operates. Similar mid-to-large scale profile with focus on prescription and specialty pharma.
• Hypera Pharma: Brazilian pharma and consumer health leader (formerly Hypermarcas), operating across prescription pharma, OTC, and consumer health segments. Comparable diversification between branded pharma and consumer/OTC categories.
• Libbs Farmacêutica: Privately-held Brazilian pharmaceutical company with focus on women's health, dermatology, and specialty therapeutics. Comparable in scale, private ownership structure, and therapeutic mix.
• EMS Pharma: Largest Brazilian pharmaceutical company by sales, with strong generics and branded portfolios. Direct competitor to Biolab in the Brazilian pharmacy channel and in generics market share (where EMS typically leads).
• Eurofarma Laboratórios: Brazilian pharmaceutical company with a similarly diversified branded and generics portfolio across multiple therapeutic areas. Comparable in scale, commercial footprint, and international expansion focus via licensing and export partnerships.

Emerging players

• Mantecorp: Brazilian pharmaceutical brand now operating under Hypera, with focus on dermatology and women's health. Comparable branded pharma presence in similar therapeutic categories.

Broad incumbents

• Sanofi: Global pharmaceutical company with substantial Brazilian operations across cardiology, dermatology, vaccines, and consumer health. Competes with Biolab as a broad incumbent rather than as a Brazilian-focused specialist.
• Bayer: Global pharmaceutical company with established Brazilian presence. Overlaps with Biolab in cardiology and women's health categories, and is also a Biolab licensing-in partner.

Regional players

• Aurobindo Pharma: Indian pharmaceutical manufacturer with global generics footprint, particularly in emerging markets. Already a Biolab licensing-in partner; comparable in generics scale and emerging market expansion model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@biolab_farmaceutica
• Facebookfacebook.com/biolabfarmaceutica
• LinkedInlinkedin.com/company/biolabfarmaceutica
• Instagraminstagram.com/biolabfarmaceutica
• TikToktiktok.com/@biolabfarmaceutica

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolab Sanus Farmaceutica